Small proline-rich protein 1A is a novel target of peroxisome proliferator-activated receptor gamma in steatotic liver disease
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2026.112456 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Daisuke Aibara und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. Electronic address: aibara@adm.fukuoka-u.…. Hauptthemen laut MEDLINE: PPAR gamma, Fatty Liver, Cornified Envelope Proline-Rich Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Fukuoka Public Health Promotion Organization Cancer Research Fund, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Peroxisome proliferator-activated receptor gamma (PPARγ) is a central regulator of lipid homeostasis; however, the specific downstream effectors mediating hepatic steatosis remain incompletely defined. In this study, we investigated the molecular basis, by which PPARγ regulates the expression of small proline-rich protein 1 A (SPRR1A) during the development of fatty liver. We initially performed a bioinformatic re-analysis of publicly available microarray datasets to characterize the gene expression profiles associated with hepatic steatosis in leptin-deficient type 2 diabetic (ob/ob) mice and patients with metabolic dysfunction-associated steatotic liver disease (MASLD). SPRR1A expression was markedly elevated in steatotic livers of both human patients and mouse models. This induction was substantially attenuated in ob/ob mice lacking hepatic Pparg, indicating a PPARγ-dependent regulatory mechanism. Consistently, increased hepatic Sprr1a expression was observed in several experimental models of fatty liver disease, including genetic (db/db), dietary (high-fat and Western diets), and alcohol-induced models. In silico transcriptomic analyses of publicly archived human liver samples further demonstrated significantly higher SPRR1A expression in patients with fatty liver disorders, including MASLD, than in non-steatotic controls. Reporter gene and electrophoretic mobility shift analyses demonstrated that PPARγ directly activated Sprr1a transcription through a conserved PPARγ-responsive element in its promoter. Collectively, these results identify Sprr1a as a previously unrecognized transcriptional target of PPARγ in the context of hepatic steatosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. Electronic address: aibara@adm.fukuoka-u.ac.jp.
- Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
Förderung
- Fukuoka Public Health Promotion Organization Cancer Research Fund
- Japan Society for the Promotion of Science
Zitieren
APA
Aibara, D., & Matsusue, K. (2026). Small proline-rich protein 1A is a novel target of peroxisome proliferator-activated receptor gamma in steatotic liver disease. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2026.112456
Vancouver
Aibara D, Matsusue K. Small proline-rich protein 1A is a novel target of peroxisome proliferator-activated receptor gamma in steatotic liver disease. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2026.112456
BibTeX
@article{Aibara2026,
author = {Aibara, Daisuke and Matsusue, Kimihiko},
title = {Small proline-rich protein 1A is a novel target of peroxisome proliferator-activated receptor gamma in steatotic liver disease},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2026.112456}
}
EUVIMED